Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note published on Wednesday,Benzinga reports. They currently have a $221.00 target price on the stock.

KRYS has been the topic of several other research reports. Chardan Capital reissued a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $210.00.

Krystal Biotech Stock Up 2.9 %

NASDAQ KRYS opened at $187.86 on Wednesday. The firm has a market cap of $5.40 billion, a PE ratio of 62.83 and a beta of 0.84. Krystal Biotech has a 52 week low of $107.50 and a 52 week high of $219.34. The company has a 50 day moving average price of $157.37 and a 200 day moving average price of $175.23.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 EPS. On average, equities research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after purchasing an additional 21,133 shares during the period. Vanguard Group Inc. lifted its stake in shares of Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares during the period. State Street Corp lifted its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).